Selegiline    (DrugBank: Selegiline)

1 disease
IDDisease name (Link within this page)Number of trials
6Parkinson disease16

6. Parkinson disease    [ 2,123 clinical trials,   2,046 drugs,   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
16 / 2,123 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2000037828
2020-09-012020-09-02Clinical study of Wuqinxi combined with selegilan in improving frozen gait of Parkinson's diseaseClinical study of Wuqinxi combined with selegilan in improving frozen gait of Parkinson's disease Parkinson's diseaseGroup 1:Routine anti PD treatment + stretching training;Group 2:Routine anti PD treatment + stretching training + selegiline;Group 3:Routine anti PD treatment + Wuqinxi training;Group 4:Routine anti PD treatment + Wuqinxi training + selegiline;Union Medical College Affiliated Hospital of Tongji Medical College, Huazhong University of science and technologyNULLRecruiting4080MaleGroup 1:30;Group 2:30;Group 3:30;Group 4:30;China
2ChiCTR1800018017
2018-10-302018-08-27Clinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early Parkinson‘s Disease symptoms and delaying the progression of the diseaseClinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early Parkinson‘s Disease symptoms and delaying the progression of the disease Parkinson's diseaseTreatment group:Selegiline+Shudipingchan granule;Control group:Selegiline+TCM simulant;Longhua Hospital Shanghai University of Traditional Chinese MedicineNULLPending3085BothTreatment group:92;Control group:92;China
3ChiCTR1800017949
2018-10-302018-08-24Clinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early PD symptoms and delaying the progression of the diseaseClinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early PD symptoms and delaying the progression of the disease Parkinson's diseaseGroup 1:Selegiline and Shudipingchan granule;Group 2:Selegiline and simulant TCM granule;Longhua Hospital Shanghai University of Traditional Chinese MedicineNULLPending3085BothGroup 1:72;Group 2:72;China
4ChiCTR1800015331
2018-04-012018-03-23Dopaminergic Mechanisms of Temporal Working Memory in Parkinson's DiseaseDopaminergic Mechanisms of Temporal Working Memory in Parkinson's Disease Parkinson's diseasede novo PD patients:levodopa 4 weeks;de novo PD patients:pramipexole 4 weeks;de novo PD patients:selegiline 4 weeks;Institute of Psychology, Chinese Academy of SciencesNULLRecruiting5080Bothde novo PD patients:50;de novo PD patients:50;de novo PD patients:50;China
5JPRN-jRCTs051180098
09/06/201606/03/2019The DAT-SPECT study for the benefit of Selegilline or Zonisamide in Parkinson's DiseaseA comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's disease Parkinson's disease;034034L-Dopa/DCI only : The drug is administered per oral at 300 mg/day. The treatment is started within 14 days after registration and continued until day 365.
L-Dopa/DCI + selegiline : L-Dopa/DCI is administered per oral at 300 mg/day and selegiline is administered at 5 mg/day. The treatment is started within 14 days after registration and continued until day 365.
L-Dopa/DCI + zonisamide : L-Dopa/DCI is administered per oral at 300 mg/day and zonisamide is administered at 25 mg/day. The treatment is started within 14 days after registration and continued until day 365.
Ito HidefumiNULLRecruiting>= 55age old< 80age oldBoth120Phase 2Japan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6JPRN-UMIN000022533
2016/06/0101/06/2016A comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's disease Parkinson's diseaseL-Dopa/DCI only
The drug is administered per oral at 150 to 300 mg/day. The treatment is started within 14days after registration and continued until day 365.
L-Dopa/DCI + selegiline
L-Dopa/DCI is administered per oral at 150 to 300 mg/day and selegiline is administered at 5mg/day. The treatment is started within 14days after registration and continued until day 365.
L-Dopa/DCI + zonisamide
L-Dopa/DCI is administered per oral at 150 to 300 mg/day and zonisamide is administered at 25mg/day. The treatment is started within 14days after registration and continued until day 365.
Osaka Redcross HospitalWakayama Prefectural Medical CollegeNULLRecruiting55years-old80years-oldMale and Female180Phase 2Japan
7EUCTR2014-000335-17-GB
(EUCTR)
28/10/201423/07/2014Rotigotine and memory in Parkinson's.The Effect of Rotigotine on Memory in Idiopathic Parkinson's Disease without Cognitive Impairment - Rotigotine and Memory in Parkinson's. Idiopathic Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: rotigotine
INN or Proposed INN: Rotigotine
Product Name: levodopa CR (controlled release)
INN or Proposed INN: levodopa
Product Name: Rasagiline
INN or Proposed INN: Rasagiline
Product Name: Selegiline
INN or Proposed INN: selegiline
Research and Development University Hospital of North StaffordshireKeele UniversityNot RecruitingFemale: yes
Male: yes
0United Kingdom
8NCT02225548
(ClinicalTrials.gov)
September 201422/8/2014Sagene 2014 - Parkinson's Disease and Erectile DysfunctionAn Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction.Parkinson's Disease;Erectile DysfunctionDrug: Selegiline;Drug: TadalafilUniversity of South FloridaNULLRecruiting40 Years64 YearsMale10Phase 4United States
9JPRN-UMIN000008477
2012/07/1919/07/2012Clinical study of selegiline hydrochloride ( FP OD tablet 2.5) to flexion of spine in Parkinson's disease. Parkinson diseaseSelegiline hydrochloride 5mg 8weeks, 7.5mg 8weeks and stop it, followed after 8weeks, and evaluate each points.Department of Neurology, Juntendo Koshigaya HospitalNULLComplete: follow-up complete20years-oldNot applicableMale and Female20Not selectedJapan
10JPRN-JapicCTI-122000
01/4/201202/11/2012Long-term study of FPF1100NW monotherapyLong-term study on FPF1100NW monotherapy with early Parkinson's disease patients Early Parkinson's diseaseIntervention name : FPF1100NW
INN of the intervention : Selegiline
Dosage And administration of the intervention : oral
Control intervention name : null
FP Pharmaceutical Corp.NULLBOTH130Phase 2NULL
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2010-020769-25-FR
(EUCTR)
10/08/201009/07/2010Evaluation médico-économique de l’infusion continue intra-duodénale d’une forme gélifiée de levodopa dans le traitement des formes avancées et sévères de maladie de parkinson par l’intermédiaire d’un dispositif médicalEvaluation médico-économique de l’infusion continue intra-duodénale d’une forme gélifiée de levodopa dans le traitement des formes avancées et sévères de maladie de parkinson par l’intermédiaire d’un dispositif médical Parkinson's disease
MedDRA version: 12.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated
Trade Name: DUODOPA
INN or Proposed INN: LEVODOPA/CARBIDOPA
INN or Proposed INN: LEVODOPA/BENZERASIDE
INN or Proposed INN: PERGOLIDE
INN or Proposed INN: LISURIDE
INN or Proposed INN: BROMOCRIPTINE
INN or Proposed INN: ROPINIROLE
INN or Proposed INN: PRAMIPEXOLE
INN or Proposed INN: IPRONIAZID
Other descriptive name: MOCLOBEMIDE
INN or Proposed INN: AMANTADINE
INN or Proposed INN: CLOZAPINE
INN or Proposed INN: SELEGILINE
INN or Proposed INN: RASAGILINE
INN or Proposed INN: ENTACAPONE
INN or Proposed INN: TOLCAPONE
CHU de PoitiersNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
France
12NCT00443872
(ClinicalTrials.gov)
March 20073/3/2007Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine AgonistsAdding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing ComplicationsParkinson's DiseaseDrug: orally disintegrating selegiline (Zelapar)Parkinson's Disease and Movement Disorder Center of Boca RatonValeant Pharmaceuticals International, Inc.Completed30 Years90 YearsAll77Phase 4United States
13NCT00640159
(ClinicalTrials.gov)
January 200718/3/2008Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's DiseaseTolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease.Parkinson's DiseaseDrug: ZelaparBaylor College of MedicineNULLCompleted30 Years90 YearsBoth55Phase 4United States
14EUCTR2006-005140-89-NL
(EUCTR)
11/12/200601/12/2006A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS - Tyramine challenge studyA PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS - Tyramine challenge study This postmarketing Phase I study is performed in healthy volunteers. The IMP rasagiline 1mg is indicated for the treatment of Parkinson's Disease (PD).
MedDRA version: 9.1;Level: PT;Classification code 10061536
Trade Name: Selegiline HCl 5 PCH
Trade Name: Nardil
Product Name: Rasagiline 1mg tablet
Product Code: TVP-1012
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesilate
Product Name: Rasagiline 2 mg tablet
Product Code: TVP-1012
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesilate
TEVA Pharmaceuticals Industries LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
160Phase 1Netherlands
15JPRN-JapicCTI-101020
Phase II study on FPF1100NW monotherapyStudy on FPF1100NW monotherapy with early Parkinson's disease patients (Phase II study) Parkinson's diseaseIntervention name : FPF1100NW
INN of the intervention : Selegiline
Dosage And administration of the intervention : oral
Control intervention name : null
FP Pharmaceutical Corp.NULL2074BOTH90Phase 2NULL
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16JPRN-JapicCTI-121954
Phase III study on FPF1100NW monotherapyRandomized, double-blind, placebo-controlled study on FPF1100NW monotherapy with early Parkinson's disease patients (Phase III study) Early Parkinson's diseaseIntervention name : FPF1100NW
INN of the intervention : Selegiline
Dosage And administration of the intervention : oral
Control intervention name : null
FP Pharmaceutical Corp.NULL2074BOTH280Phase 3NULL